BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2586008)

  • 1. Tumor-associated trypsin inhibitor in patients with chronic pancreatic diseases.
    Plebani M; Basso D; Fabris C; Meggiato T; Del Favero G; Panozzo MP; Fogar P; Faggian D; Angonese C; Burlina A
    Klin Wochenschr; 1989 Oct; 67(20):1029-32. PubMed ID: 2586008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated trypsin inhibitor in pancreatic diseases.
    Aroasio E; Piantino P
    Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    J Cancer Res Clin Oncol; 1994; 120(8):494-7. PubMed ID: 8207049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of pancreatic secretory trypsin inhibitor by radioimmunoassay in diagnosis of pancreatic diseases].
    Chen BG
    Zhonghua Wai Ke Za Zhi; 1988 Dec; 26(12):714-6, 780. PubMed ID: 3248462
    [No Abstract]   [Full Text] [Related]  

  • 5. [Determination of tumor-associated trypsin inhibitor (TATI) in subjects with gastrointestinal diseases. Preliminary data].
    Piantino P; Mosso R; Polloni R; Cerchier A; Gennaretti G; Daziano E
    Minerva Med; 1989 Mar; 80(3):199-203. PubMed ID: 2717042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biology and function of tumor-associated trypsin inhibitor, TATI.
    Stenman UH; Koivunen E; Itkonen O
    Scand J Clin Lab Invest Suppl; 1991; 207():5-9. PubMed ID: 1780691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Serum pancreatic secretory trypsin inhibitor (PSTI), amylase activity and pancreatic isoamylase activity in pancreatic diseases].
    Suehiro I; Otsuki M; Oka T; Okabayashi Y; Ohki A; Kanda T; Yuu H; Maeda M; Yamasaki T; Baba S
    Nihon Shokakibyo Gakkai Zasshi; 1984 Apr; 81(4):1044-9. PubMed ID: 6205183
    [No Abstract]   [Full Text] [Related]  

  • 8. Appearance mechanism and molecular heterogeneity of serum pancreatic secretory trypsin inhibitor (PSTI).
    Nakano I; Funakoshi A; Sumii T; Miyazaki K; Oogami Y; Kimura T; Ibayashi H
    Gastroenterol Jpn; 1985 Aug; 20(4):354-60. PubMed ID: 4054512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunoassay for human pancreatic secretory trypsin inhibitor: measurement of serum pancreatic secretory trypsin inhibitor in normal subjects and subjects with pancreatic diseases.
    Kitahara T; Takatsuka Y; Fujimoto KI; Tanaka S; Ogawa M; Kosaki G
    Clin Chim Acta; 1980 Apr; 103(2):135-43. PubMed ID: 6154549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between serum concentrations of three specific exocrine pancreatic proteins and pancreatic duct morphology at ERCP examinations.
    Borgström A; Wehlin L
    Scand J Gastroenterol; 1984 Mar; 19(2):220-7. PubMed ID: 6201996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnostic value of serum pancreatic secretory trypsin inhibitor (PSTI) in acute pancreatitis].
    Chen BG
    Zhonghua Wai Ke Za Zhi; 1988 Jun; 26(6):365-6, 384. PubMed ID: 3229243
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum pancreatic secretory trypsin inhibitor in pancreatic disease.
    Otsuki M; Oka T; Suehiro I; Okabayashi Y; Ohki A; Yuu H; Baba S
    Clin Chim Acta; 1984 Sep; 142(2):231-40. PubMed ID: 6209036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
    Halila H; Lehtovirta P; Stenman UH
    Br J Cancer; 1988 Mar; 57(3):304-7. PubMed ID: 3162682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The measurement of serum immunoreactive pancreatic secretory trypsin inhibitor in gastrointestinal cancer and pancreatic disease.
    Satake K; Inui A; Sogabe T; Yoshii Y; Nakata B; Tanaka H; Chung YS; Hiura A; Umeyama K
    Int J Pancreatol; 1988 Jul; 3(5):323-31. PubMed ID: 2459273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of CEA, CA 19-9, CA-50, CA-195, and TATI with special reference to pancreatic disorders.
    Masson P; Pålsson B; Andren-Sandberg A
    Int J Pancreatol; 1991 May; 8(4):333-44. PubMed ID: 1791319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic secretory trypsin inhibitor-like immunoreactivity in pancreatectomized patients.
    Halila H; Huhtala ML; Schröder T; Kiviluoto T; Stenman UH
    Clin Chim Acta; 1985 Dec; 153(3):209-16. PubMed ID: 3935345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies.
    Solakidi S; Dessypris A; Stathopoulos GP; Androulakis G; Sekeris CE
    Clin Biochem; 2004 Jan; 37(1):56-60. PubMed ID: 14675563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum pancreatic enzymes and enzyme inhibitor as a tumor marker for pancreatic cancer].
    Ogawa M
    Rinsho Byori; 1986 Nov; 34(11):1229-35. PubMed ID: 2434691
    [No Abstract]   [Full Text] [Related]  

  • 19. TATI as a biomarker.
    Itkonen O; Stenman UH
    Clin Chim Acta; 2014 Apr; 431():260-9. PubMed ID: 24583226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-associated trypsin inhibitor (TATI) in the diagnosis of lung cancer.
    Pecchio F; Rapellino M; Baldi S; Casali V; Libertucci D; Coni F
    Scand J Clin Lab Invest Suppl; 1991; 207():63-4. PubMed ID: 1780695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.